Thirty patients had tumor markers within 30 days of starting treatment and periodically while on treatment (pancreastatin, gastrin, glucagon, neurotensin; metenephrines for pheochromocytoma/paraganlgioma). The gene discussed is GCG; the disease is hereditary pheochromocytoma-paraganglioma.